Several treatments have been proven to be effective for variceal bleeding in patients with cirrhosis. The aim of this multicenter, prospective, cohort study was to assess how these treatments are used in clinical practice and what are the posttherapeutic prognosis and prognostic indicators of upper digestive bleeding in patients with cirrhosis. A training set of 291 and a test set of 174 bleeding cirrhotic patients were included. Treatment was according to the preferences of each center and the follow-up period was 6 weeks. Predictive rules for 5-day failure (uncontrolled bleeding, rebleeding, or death) and 6-week mortality were developed by the logistic model in the training set and validated in the test set. Initial treatment controlled bleeding in 90% of patients, including vasoactive drugs in 27%, endoscopic therapy in 10%, combined (endoscopic and vasoactive) in 45%, balloon tamponade alone in 1%, and none in 17%. The 5-day failure rate was 13%, 6-week rebleeding was 17%, and mortality was 20%. Corresponding findings for variceal versus nonvariceal bleeding were 15% versus 7% (P ‫؍‬ .034), 19% versus 10% (P ‫؍‬ .019), and 20% versus 15% (P ‫؍‬ .22). Active bleeding on endoscopy, hematocrit levels, aminotransferase levels, Child-Pugh class, and portal vein thrombosis were significant predictors of 5-day failure; alcohol-induced etiology, bilirubin, albumin, encephalopathy, and hepatocarcinoma were predictors of 6-week mortality. Prognostic reassessment including blood transfusions improved the predictive accuracy. All the developed prognostic models were superior to the Child-Pugh score. In conclusion, prognosis of digestive bleeding in cirrhosis has much improved over the past 2 decades. Initial treatment stops bleeding in 90% of patients. Accurate predictive rules are provided for early recognition of high-risk patients. (HEPATOLOGY 2003;38:599-612.) 
A lthough randomized controlled trials have shown that mortality from variceal bleeding in cirrhosis has decreased over the past 3 decades from about 50% to 20% to 30%, 1 this figure is still remarkably high. This important reduction in mortality likely is related to a more efficient approach to upper digestive bleeding in patients with cirrhosis, based on improved supportive measures, early administration of reducing portal pressure drugs, widespread use of emergency endoscopic treatments, and, more recently, the introduction of salvage transjugular intrahepatic portosystemic shunt. [2] [3] [4] However, how the results of randomized controlled trials apply to clinical practice, to what extent they affect the diagnostic and therapeutic approach, and what the present day outcome and prognostic indicators of cirrhotic patients with upper digestive bleeding treated outside clinical trials are, is unknown.
For these reasons, we assessed the management strategies and the 6-week outcome and prognostic indicators of a large prospective cohort (training set) of cirrhotic patients presenting with upper digestive bleeding in a large sample of medical or gastroenterologic departments in Italy. Prognostic indicators were validated in a subsequent independent validation set of patients (the test set) and compared with the Child-Pugh score. 5 tients consecutively admitted for hematemesis and/or melena were included. Diagnosis of cirrhosis was based on a previous liver biopsy or on compatible clinical, laboratory, and imaging findings. To achieve a patient sample as representative as possible of the bleeding cirrhotic population, no exclusions were planned. Variceal size was defined according to the criteria of the Italian Liver Cirrhosis Project 6 as small, medium, and large. Red signs on varices were classified as present or absent. The source of bleeding was proven endoscopically in all patients in whom the hemodynamic conditions allowed for endoscopy. It was agreed that patients should be treated according to the standard policy in use in each center.
The training set consisted of 291 patients consecutively observed in the participating centers between October 1997 and January 1998 and the test set of 174 patients seen between February 1999 and April 1999. The collection of data record forms was completed by the end of 1999 and the process of analysis, interpretation of results, and drafting of the study report required a number of meetings of the participants.
Definitions and Data Collection. To improve the homogeneity of data collection, 2 investigator meetings were held before starting the study to discuss and approve the study protocol and the data record form.
In addition to the medical history and baseline characteristics, the following information was recorded: (1) time intervals from start of bleeding to hospital admission, from admission to endoscopy, and from start of bleeding to endoscopy; (2) source and activity of bleeding; (3) type and outcome of initial treatment; (4) 5-day and 6-week rebleeding and mortality rates. The Child-Pugh score 5 was computed for each patient. Whenever possible, liver ultrasound examination was performed to identify liver cancer or portal vein thrombosis if previously unknown.
The following definitions were based on the recommendations of the Baveno I and II consensus workshops 7, 8 : (1) time zero of the bleeding episode: the time of admission to the first hospital to which the patient was taken; (2) source of bleeding: a lesion actively bleeding or with adherent clot, white nipple, or presence of a single lesion without other potential sources of bleeding; (3) active bleeding on endoscopy: bleeding was defined as active if a spurting or oozing lesion was seen; the presence of a white nipple on varices, adherent clots on varices or ulcers, or a visible vessel in the base of an ulcer were considered as stigmata of recent hemorrhage; when neither spurting nor stigmata were seen the bleeding was considered nonactive; (4) bleeding duration: the acute bleeding episode was considered finished at the beginning of the first 24-hour interval with no hematemesis, stable hemoglobin concentration without blood transfusions, stable hemodynamic conditions (absence of systolic blood pressure reduction of 20 mm Hg or more and increase of heart rate of 20/min or more); (5) first rebleeding episode: any occurrence of hematemesis or hemoglobin drop without hematemesis if fresh melena also was observed, after the initial bleeding episode was considered finished.
Five-day failure was defined as failure to control bleeding, rebleeding, or death within 5 days of admission. Follow-up was 42 days. Rebleeding episodes and mortality during this period were recorded. No patient was lost to follow-up evaluation.
Statistical Analysis. Patients' characteristics at inclusion in the study were described as proportions or means with SD. Differences between means were assessed by the Student's t test or analysis of variance, as appropriate, and differences observed on contingency tables were assessed by the 2 test. Cumulative proportions of patients free of the outcomes of interest were computed by the Kaplan and Meier method and the observed differences were assessed by the log-rank test. 9 The logistic model 10 was used to assess prognostic indicators for 5-day failure and 6-week mortality. We considered this model an appropriate alternative to the use of the Cox model because of the very short follow-up time and the completeness of follow-up evaluation in all patients. Candidate prognostic variables for each outcome of interest included those already known as predictive from previous studies [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and several other variables we considered clinically relevant. To reduce the risk for overfitting the prognostic models, it was stated that the ratio of candidate prognostic variables to the number of observed events should be 1:5 or less in each final model. 24 For this purpose, the most significant variables were selected for the final model from several clusters of variables according to the following items: cause of liver disease and demography, previous clinically relevant events, clinical presentation, time intervals relevant to the bleeding episode, endoscopic findings, and treatment for the acute bleeding. A separate model was then built up by including some relevant early follow-up variables to assess whether clinical information available within 24 hours from admission and after control of initial bleeding may improve the prognostic assessment. When both the Child-Pugh score (or class) and single components were significant at univariable analysis, 2 multivariable models were developed by including alternatively the components or the score (or class) to avoid redundancy. The multivariable analyses were performed according to a backward step-wise procedure. For the significant variables the ␤ coefficients and odds ratios with 95% confidence intervals are reported. From the analyses performed in the training set a prediction model for each relevant outcome was developed. The predictive accuracy of each model was assessed by the concordance (c)-statistic. 25, 26 This statistic usually is used to evaluate diagnostic tests. A c-statistic greater than 0.7 generally is considered as indicating a useful test and a c-statistic between 0.8 and 0.9 indicates excellent diagnostic accuracy. Each prediction model then was validated by comparing the area under the receiver operating characteristic curve in the training and in the test set by a 2 test. 25, 26 The area under the receiver operating characteristic curve of each prediction model was then compared with that of the Child-Pugh score using the same test. The calculation of a prognostic index (PI) in individual patients and of the relevant operating characteristics (sensitivity, specificity, odds ratio, likelihood ratio, and error rate) and their interpretation are shown in Appendix A.
Because bleeding from varices is widely considered to be associated with a worse prognosis than bleeding from other sources, a separate prognostic analysis was performed for variceal bleeding, whereas the insufficient number of outcome events did not allow for a separate analysis in nonvariceal bleeding.
All the statistical analyses were performed by STATA 7 (Stata Corporation, College Station, TX).
Ethics. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the local hospital ethics committees for human investigations.
Results
Relevant characteristics of the 465 patients on admission are reported in Table 1 . At least one previous bleeding episode had occurred in 246 patients and 111 of them were not receiving any prophylactic treatment for rebleeding when included in the present study. Yet, among 200 patients without previous bleeding only 14 (7%) were receiving primary prophylaxis for bleeding (␤-blockers, n ϭ 12). 12 The median time from start of bleeding to hospital admission was 3 hours, and from admission to endoscopy was 2 hours ( Table 1 ). The most frequent sources of bleeding were esophagogastric varices (336 of 465 or 72%); an actively bleeding lesion was found on endoscopy in 180 of 465 patients (39%) ( Table 2) . Endoscopy was not performed in 13 patients because of the following reasons: massive bleeding with encephalopathy, ascites, and jaundice in 3 patients; encephalopathy, tense ascites, and deep jaundice in 1 patient; massive bleeding and hypotension in 4 patients; and reason not reported in 5 patients.
Treatment. The initial treatments used to control bleeding and details on blood transfusions are reported in Table 3 . Balloon tamponade was used alone in 5 patients and together with other treatments in 46 other patients ( Table 3) .
The combination of endoscopic and pharmacologic treatment was used more frequently in patients actively bleeding or with stigmata of recent bleeding at endoscopy (231 of 336; 69%) than in patients with nonactive bleeding (26 of 129; 20%) (P Ͻ .00001). An endoscopic treatment was used alone in 46 patients, and a vasoactive drug alone (mostly somatostatin or octreotide) was used in 124. When an endoscopic treatment was used, sclerotherapy was by far the most frequently preferred (243 of 257, 94%), whereas octreotide and somatostatin were the main pharmacologic treatments (272 of 335, 81%). Initial treatment controlled bleeding in 418 of 465 (90%) patients, whereas in 27 patients a change of initial treatment was deemed necessary because of one or a combination of the following criteria: excessive need for transfusion in 9 patients, new hematemesis in 12 patients, continuing melena in 14 patients, a decrease in hemoglobin level in 14 patients, and hemodynamic instability in 19 patients (systolic blood pressure reduction in 12 patients; tachycardia in 7 patients). Therefore, overall, initial bleeding was controlled in 445 of 465 (96%). The median time from admission to bleeding control was 18 hours (range, 0-120 h; Fig. 1 ).
In 20 patients bleeding was not controlled despite immediate combination of pharmacologic and endoscopic therapy and balloon tamponade as appropriate. In these 20 patients, the cause of bleeding was esophageal varices in 13 (65%), gastric varices in 4 (20%), portal hypertensive gastropathy in 1, peptic ulcer in 1, and undefined in 1. In none of these patients did clinical conditions allow for placing transjugular intrahepatic portosystemic shunt.
Five-Day Failure. Five-day failure rate was 36 of 255 (12.4%) in the training set and 24 of 174 (13.8%) in the test set (P ϭ .66). Overall, 5-day failure occurred in 60 of 465 (12.9%) patients (Table 4) . Of these, 5 did not achieve control of bleeding and were alive on day 5, 15 rebled and were alive on day 5, and 40 died (20 from uncontrolled initial bleeding, 3 from uncontrolled re- bleeding, 11 from liver failure, 4 from advanced hepatocellular carcinoma, and 2 from hepatorenal syndrome). Five-day failure rate was significantly higher in patients bleeding from varices than from other sources (49 of 336 vs. 8 of 114; P ϭ .03).
Rebleeding.
A treatment for the prevention of rebleeding was given to 233 of 465 patients (50%): a nonselective ␤-blocker Ϯ isosorbide mononitrate was given to 81, isosorbide mononitrate alone was given to 16, sclerotherapy was given to 82, banding ligation was given to 19, pharmacologic plus endoscopic therapy was given to 45, and shunt surgery was given to 2.
Rebleeding rate was 46 of 291 (15.8%) in the training set and 31 of 174 (17.8%) in the test set (P ϭ .57). Overall, 77 of 465 patients (16.6%) rebled within 6 weeks ( Table 4 ). The rebleeding rate was significantly higher in patients with initial bleeding from varices than in those who had bled from other sources (64 of 336 or 19.1% vs. 11 of 114 or 9.6%; P ϭ .019) ( Table 4 , Fig. 2 ). Eighteen patients rebled within 5 days and 59 patients rebled from day 6 to 42 (Table 4) .
Rebleeding risk was not significantly different according to the portal hypertensive sources of initial bleeding: 55 of 297 (18%) for esophageal varices, 9 of 39 (23%) for gastric varices, and 8 of 44 (18%) for portal hypertensive gastropathy (P ϭ .78).
The mean number Ϯ SD of rebleeding episodes was 1.6 Ϯ 2 in the 46 patients who rebled in the training set (total 96 episodes) and 1.3 Ϯ 0.7 in the 31 rebleeders in the test set (total 52 episodes) (t ϭ .78; P ϭ .44).
Rebleeding sources are reported in Table 4 according to the source (varices vs. other) of the initial bleeding. Rebleeding from varices was more frequent in patients with initial bleeding from varices than from other sources (47/336 or 14% vs. 4/114 or 3.5%; P ϭ .002).
Mortality. Deaths were 60 of 291 (20.6%) in the training set and 32 of 174 (18.4%) in the test set (P ϭ .56). Overall, 92 patients (20%) died within 6 weeks, 40 within 5 days, and 52 from day 6 to 42. Mortality was remarkably higher for patients bleeding from varices than for patients bleeding from other sources although the difference failed to reach statistical significance either within 5 days (9.2% vs. 5.3%; P ϭ .18) or within 6 weeks (20.8% vs. 14.9%; P ϭ .16) ( Table 4 ; Fig. 3 ). Causes of death are reported in Table 4 according to the source of the initial bleeding.
Prognostic Indicators. The list of candidate prognostic variables and those significant at univariable analysis is reported in Table 5 according to relevant clusters. Significant variables in the final multivariable models are re- Fig. 2 . Cumulative proportions of patients rebleeding according to the source of initial bleeding in the 450 patients with known source of bleeding. "Varices" denotes patients with initial bleeding from varices. "Other" denotes patients with initial bleeding from other sources. Numbers below the abscissa are the numbers of patients still at risk per each observation period. P value refers to the log-rank test. Fig. 3 . Cumulative proportions of patients dying according to the source of initial bleeding in the 450 patients with known source of bleeding. "Varices" denotes patients with initial bleeding from varices. "Other" denotes patients with initial bleeding from other sources. Numbers below the abscissa are the numbers of patients still at risk for each observation period. P value refers to the log-rank test.
ported in Tables 6 and 7 . Per each outcome, 2 models were separately built. Model I, including only variables available on admission, and model II, including early follow-up variables. The early follow-up variables include the 12-hour and 24-hour persistence of bleeding, the number of blood units transfused within 24 hours of admission, the total number of blood units transfused until control of bleeding, and rebleeding within 5 days. Among these, only the 12-and 24-hour follow-up variables were included in the analysis of prognostic indicators for 5-day failure (Table 5 ). Significant prognostic indicators at multivariable analysis in the training set are reported in Table  6 for 5-day failure and in Table 7 for 6-week mortality. The corresponding prognostic models are reported in Tables 8 and 9. In general, all the models were based on variables related to the severity of initial bleeding and liver function. In addition, portal vein thrombosis was mostly a predictor of 5-day failure and hepatocellular carcinoma was mostly a predictor of death. Concordance (c)-statistic (Tables 8 and 9 ) yielded values from 0.73 to 0.84 for all the models in the test set indicating fair to excellent predictive accuracy. The validity of the models is shown in Tables 8 and  9 : the area under the receiver operating characteristic curve per each model in the test set was not significantly different from the corresponding area in the training set, indicating that the predictive sensitivity and specificity observed in the training set were fairly reproduced in the test set. Corresponding figures in the whole series of 465 patients are reported too. Comparison with the Child-Pugh score (Tables  8 and 9) shows that the developed models are more accurate predictors than the Child-Pugh score for all the assessed outcomes, although the differences failed to reach statistical significance for mortality in the test set because of a type II error.
Comparison of the receiver operating characteristic curves Abbreviations: HBsAg, hepatites B surface antigen; Anti-HCV, antibody to hepatites C virus; NSAID, nonsteroidal anti-inflammatory drug; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PSE, portal systemic encephalopathy.
*Statistically significant (P Ͻ .05) for 5-day failure in the whole series of patients (n ϭ 291). †Statistically significant (P Ͻ .05) for 5-day failure in variceal bleeders (n ϭ 207). ‡Statistically significant (P Ͻ .05) for 6-week mortality in the whole series of patients (n ϭ 291). §Statistically significant (P Ͻ .05) for 6-week mortality in variceal bleeders (n ϭ 207). for the prediction of mortality with the developed models and the Child Pugh score in the whole series of patients is shown in Fig. 4 . Details on the operating characteristics of the developed models are reported in Appendix A.
Discussion
This large prospective cohort study provides a reassessment of the prognosis of upper digestive bleeding in cirrhosis on the basis of a large prospective cohort. The results have been validated in a further independent prospective cohort. To make the results as generalizable as possible, no patients were excluded and the described events were defined according to the statements of large consensus conferences. 7, 8 The most important finding of this study is the striking reduction of mortality as compared with that reported 2 decades ago. In fact, mortality for variceal bleeding was 42% in the landmark cohort study reported in 1981 by Graham and Smith 12 and was 20% in the present series. This finding confirms that the reduction in mortality reported in the past 2 decades in randomized controlled trials of treatments for acute variceal bleeding from 50% to near 25% 27 has been reproduced in clinical practice. A similar finding was reported recently in a multicenter retrospective study in the United States. 3 This remarkable mortality reduction probably reflects the efficacy of the vasoactive drugs and endoscopic treatments introduced in clinical practice, as well as the more intensive approach prompted by the availability of new therapeutic options.
More than one half of the patients already had experienced a previous bleeding episode, originating from esophagogastric varices in most cases. It is of interest, however, that less than 60% of patients with a previous bleed were receiving a treatment to prevent rebleeding and that 12% of the whole series consumed nonsteroidal anti-inflammatory drugs in the 2 weeks before bleeding. These considerations suggest that much still can be performed in clinical practice to reduce the risk for bleeding in cirrhotic patients. It is of interest in this respect that insufficient prescription of treatments for the prevention of rebleeding has been reported recently in the United States. 3 The source of bleeding was variceal in 72% of patients, another defined source in 25% of patients, and undefined in 3% of patients. A vasoactive drug was used in 72% of patients and was associated with endoscopic therapy in 45% of patients, mostly in patients actively bleeding from varices, although 106 variceal bleeders who were not bleeding actively at endoscopy were also treated by sclerotherapy. Whichever the initial treatment, endoscopic, pharmacologic, or a combination of both, it achieved control of the initial bleeding in 90% of patients. Although this finding provides further evidence that available treatments are highly effective, the high mortality rate (66%) in the patients with bleeding uncontrolled by the initial treatment suggests that failure of the initial treatment identifies the patients at the highest risk for death. To what extent a wider use of emergency banding ligation, similar to the general practice in other countries, 3 may still modify the outcome of variceal bleeders should be assessed in future outcome studies.
The present study confirmed that the first 5 days after admission represent the most crucial time period for the prognosis with 40 of 92 deaths occurring during this early interval. It is also worthy to note that 17 of these deaths occurred after control of initial bleeding from liver failure and hepatorenal syndrome, whereas bleeding could not be controlled in 23. This suggests that further improvements in treatments to control bleeding might still improve the prognosis of digestive bleeding in cirrhosis and Fig. 4 . Comparison of the receiver operating characteristic curves for the predictive models and the Child-Pugh (CP) score for 6-week mortality in the whole series of patients and in patients bleeding from varices, respectively. Models I refer to the predictive rules, including PIs at admission. Models II refer to predictive rules, including early follow-up variables.
confirms that a sizable proportion of deaths probably will remain unavoidable because of end-stage liver disease.
The 6-week rebleeding rate in the present study was remarkably lower than in the study by Graham and Smith 12 (18% vs. 31%), probably reflecting the use of treatments now available for the prevention of early rebleeding, although a sizable proportion of patients (50%) did not receive prophylactic therapy in the present study. This suggests that a more appropriate use of treatments for the prevention of early rebleeding may further improve the overall outcome because rebleeding was associated significantly with the 6-week mortality, at least at univariable analysis, in this study. It is worth noting, in this respect, that although rebleeding occurred in many patients within 5 days, it occurred in only 18 of 77 (23%) of the total of patients who rebled within 6 weeks, confirming that the risk for rebleeding is high for a longer period than the first 5 days and that preventive treatments should be instituted as early as possible after control of initial bleeding. The lack of significant differences in the rebleeding risk in patients with different portal hypertensive sources of initial bleeding might be related to the use of prophylactic treatments.
Among the 92 patients who died within the 6-week observation period, only 37 (40%) died of bleeding. This finding is appreciably lower than the 60% reported by Graham and Smith, 12 and adds to the evidence that the observed outcome improvement likely is related to the treatments now available to control bleeding. Parallel to the reduction in mortality from bleeding we found a relative increase in mortality from liver failure and hepatorenal syndrome, which caused 46% of deaths. If we also consider the 4 patients who died from extensive hepatocellular carcinoma and whose ultimate mode of death was liver failure, then 50% of deaths were caused by liver failure and hepatorenal syndrome. This indicates that mortality in cirrhotic patients with upper digestive bleeding is going to be limited to those patients with severe liver failure for whom the only treatment presently available is liver transplantation and suggests that indicators of high risk for bleeding should be associated to those of liver failure to select patients for liver transplant. Information on the use of antibiotic prophylaxis was not available in this study because its use was recommended when the study was almost completed, 28,29 therefore, we could not assess how this treatment may affect overall outcome of the bleeding episode in clinical practice. This issue should be evaluated in future studies.
The prognostic analysis in this study provided further insight in the risk prediction in cirrhotic patients with digestive bleeding. Predictive rules have been provided for 5-day failure and for 6-week mortality, either independent of the bleeding source or in variceal bleeding. All the proposed prediction rules were shown to be valid, highly predictive, and fared better than the Child-Pugh score. The concordance (c)-statistic showed for all the predictive model values from 0.73 to 0.84, indicating fair to excellent predictive accuracy. In fact, in the test set, the calculated prognostic indexes allowed identification of subsets of patients with odds ratio for failure to control bleeding as high as 28 and for death as high as 11.5 (Appendix A). As a general consideration, it may be noted that the outcome predictors for variceal bleeding largely coincided with the overall predictors independent of the bleeding source and that the use of follow-up variables slightly but consistently improved the efficiency of the prediction rules. Accordingly, predictive rules for immediate prognostic assessment as well as for early follow-up reassessment are provided. It is of interest that the only follow-up variable important for the outcome prediction was the number of blood units transfused, seemingly reflecting the severity of the bleeding per se.
As in previous studies, indicators of liver dysfunction (Child-Pugh class) and of the severity of bleeding (active bleeding on endoscopy, hematocrit level) were among the predictors of early outcome. The predictive role of aspartate aminotransferase for 5-day failure may reflect the ischemic liver damage. The finding that portal vein thrombosis either previously known or newly diagnosed is a significant indicator of early prognosis was not previously reported and may help to improve the risk prediction, considering that if the diagnosis was previously unknown the information may be acquired easily by portable equipment.
Prognostic indicators of 6-week mortality were related more to the liver disease per se than to the severity of bleeding, as indicated by the alcohol-induced etiology and the severity of liver dysfunction (encephalopathy, bilirubin, and albumin). Hepatocellular carcinoma was not previously specifically reported as a death risk indicator for bleeding, although it is an obvious prognostic factor in liver disease. Also, for mortality the only follow-up variable improving the initial prognostic assessment is the number of blood units transfused during the initial bleeding episode, confirming that the prognostic assessment should be repeated after control of the initial bleeding.
In conclusion, the present study provided reliable evidence that the prognosis of upper digestive bleeding in cirrhosis has improved compared with a few decades ago. Treatments proven to be effective in randomized controlled trials are largely applied in clinical practice both for control of bleeding and for prevention of rebleeding. Indicators of bleeding severity and liver dysfunction are the most important predictors of 5-day failure and 6-week mortality. Accurate and validated predictive rules were provided for early outcome either independent of the source of bleeding or in variceal bleeding.
APPENDIX A

Calculation of the PI
According to the logistic regression model, 10 Tables 8 and 9 , whereas the rating of the variables included in the models are shown in Tables 6 and 7 . As an example, in a patient bleeding from varices in Child-Pugh class B, without known portal vein thrombosis and with aspartate aminotransferase serum value of 170 IU, the PI for 5-day failure, using the variables available on clinical presentation, is calculated as follows (model I for 5-day failure for bleeding from varices, Table 8 According to the logistic regression model, the outcome probability for a given PI is calculated as e PI /(1 Ϫ e PI ). In the earlier-described patient this probability is e Ϫ2.62 /(1 Ϫ e Ϫ2.62 ) ϭ 0.073/(1 Ϫ 0.073) ϭ 0.078. By using also the early follow-up variables for predicting 5-day failure in this patient we should use model II (Table 8 ) and include also the number of blood transfusions the patient received within 24 hours of admission. If the patient had received 1 blood unit then the PI would be (Table 8, 
The Operating Characteristics of PIs
The operating characteristics of the PI may be evaluated as it is for a diagnostic test yielding continuous values. 30 Therefore, per each given cut-off value of PI, the sensitivity and specificity for the prediction of the outcome may be calculated with the values of PI greater than or equal to the cut-off value considered positive: these values are true positives in patients in whom the outcome did occur and false positives in those in whom it did not. Accordingly, true and falsenegative predictions and the operating characteristics of PI may be calculated. As an example, using the data reported in Table A , the following parameters can be calculated.
• Sensitivity is the probability of a true positive test (PI Ն cut-off) in patients with the outcome: true positive/(true positive ϩ false negative) ϭ 180/200 ϭ 0.90.
• Specificity is the probability of a negative test (PI Ͻ cut-off) in patients in whom the outcome did not occur: true negative/(false positive ϩ true negative) ϭ 700/800 ϭ 0.88.
• The predictive value for a positive test (PI Ն cut-off), is the probability of the outcome occurrence in patients with PI greater than or equal to the cut-off value: true positive/(true positive ϩ false positive) ϭ 180/280 ϭ 0.64.
• The predictive value for a negative test (PI Ͻ cut-off), is the probability of nonoccurrence of the outcome in patients with PI less than the cut-off value: true negative/(true negative ϩ false negative) ϭ 700/720 ϭ 0.97.
• The odds ratio summarizes the overall discrimination ability of the test (the cut-off value of PI): (true positive/false negative)/(false positive/true negative) ϭ (180/20)/(100/700) ϭ 63.
• The likelihood ratio of a positive test (LRϩ) is the probability of PI greater than or equal to the cut-off value in patients with the outcome divided by the probability of PI greater than or equal to the cut-off value in patients without the outcome: (true positive/[true positive ϩ false negative])/(false positive/[false positive ϩ true negative]) (180/200)/(100/800) ϭ 7.2.
• The likelihood ratio of a negative test (LRϪ) is the probability of PI less than the cut-off value in patients with the outcome divided by the probability of PI less than the cut-off value in patients without the outcome: (false negative/[true positive ϩ false negative])/(true negative/[false positive ϩ true negative]) ϭ (20/200)/(700/800) ϭ 0.11.
• The error rate is the reciprocal of the predictive accuracy (the probability of correct prediction): 1 Ϫ ([true positive ϩ true negative]/ [true positive ϩ true negative ϩ false positive ϩ false negative]) ϭ 1 Ϫ ([180ϩ700]/1,000) ϭ 0.12.
In Table B the true and false outcome predictions per each given cut-off value of the interquartile ranges for the distribution of the relevant PIs are reported together with the odds ratios for the outcome when the PI is higher than each cut-off value. By applying the earlier reported formulas, any of the other operating characteristics for the suggested PIs may be calculated easily. NOTE. To calculate sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratio, and error rate for each cut-off value of PI for the relevant outcomes, apply the formulas given in the Appendix.
APPENDIX B
Members of the
Abbreviation: ne, not evaluable.
